HighTower Advisors LLC Has $18.21 Million Position in Zoetis Inc. $ZTS

HighTower Advisors LLC cut its position in Zoetis Inc. (NYSE:ZTS) by 39.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 253,412 shares of the company’s stock after selling 166,492 shares during the quarter. HighTower Advisors LLC’s holdings in Zoetis were worth $18,210,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ZTS. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Zoetis during the second quarter worth $25,000. Dunhill Financial LLC grew its stake in shares of Zoetis by 519.3% in the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after acquiring an additional 296 shares in the last quarter. Prosperity Bancshares Inc bought a new position in Zoetis during the fourth quarter worth about $25,000. Cassaday & Co Wealth Management LLC bought a new position in Zoetis during the first quarter worth about $28,000. Finally, Root Financial Partners LLC raised its stake in Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ZTS. UBS Group cut their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Friday, August 7th. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Piper Sandler dropped their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, August 10th. Zacks Research cut Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Finally, Citigroup reduced their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average price target of $101.08.

Zoetis Trading Down 3.0%

ZTS opened at $73.56 on Wednesday. The stock has a market capitalization of $30.40 billion, a price-to-earnings ratio of 12.12, a P/E/G ratio of 1.77 and a beta of 0.73. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $152.12. The company has a 50-day simple moving average of $75.61 and a 200 day simple moving average of $92.87.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s quarterly revenue was down .2% compared to the same quarter last year. During the same period last year, the firm earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts predict that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.